Tacrolimus 0.02% Ophthalmic Solution

Tacrolimus 0.02% Ophthalmic Solution is for topical ophthalmic use and commonly prescribed as a tear supplement for the treatment of dry eye.

• Volume: 5ml
• Concentration: 0.02%
  • Also available as 0.03%
• We exclusively compound Tacrolimus 0.02% Ophthalmic Solution for ophthalmic use only
• Compounded in a sterile compounding facility that is <795>, <797> and <800> chapter compliant

References:

1. Alghamdi AH. Clinical applications of tacrolimus in the treatment of ocular diseases: a narrative literature review. Int Ophthalmol. 2026;46(1):1. PMID: 41264132. PMCID: PMC12634772. https://pmc.ncbi.nlm.nih.gov/articles/PMC12634772/
2. Koh K, Jun I, Kim TI, Kim EK, Seo KY. Long-term results of topical 0.02% tacrolimus ointment for refractory ocular surface inflammation in pediatric patients. BMC Ophthalmol. 2021;21:255. PMID: 34088281. PMCID: PMC8178927. https://pmc.ncbi.nlm.nih.gov/articles/PMC8178927/
3. Zhai J, Gu J, Yuan J, Chen J. Tacrolimus in the treatment of ocular diseases. BioDrugs. 2011;25(2):89–103. doi: 10.2165/11587010-000000000-00000. https://link.springer.com/article/10.2165/11587010-000000000-00000
4. Jung JW, Lee YJ, Yoon SC, Kim TI, Kim EK, Seo KY. Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease. Am J Ophthalmol. 2015;159(3):519–527.e1. PMID: 25498356. https://pubmed.ncbi.nlm.nih.gov/25498356/
5. Nagra PK, Rapuano CJ, Cohen EJ, Laibson PR. Thygeson’s superficial punctate keratitis: ten years’ experience. Ophthalmology. 2004;111(1):34–37. PMID: 14711711. https://pubmed.ncbi.nlm.nih.gov/14711711/